Telomerase activity - A prognostic factor in colorectal cancer?

Onkologie

Volumn 28, Issue 11, 2005, Pages 550-551

  Brümmendorf, Tim H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CANCER VACCINE; DNA; RIBONUCLEOPROTEIN; RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

AGING; CANCER CYTODIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STAGING; CHROMOSOME ANALYSIS; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; CYTOGENETICS; DISEASE ASSOCIATION; DNA REPLICATION; DRUG TARGETING; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; FOLLOW UP; GENETIC STABILITY; GERM CELL; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIVARIATE ANALYSIS; PHARMACODYNAMICS; PROGNOSIS; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; RECTUM CANCER; RISK ASSESSMENT; SOLID TUMOR; SOMATIC CELL; TUMOR LOCALIZATION;

CLINICAL TRIALS; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; HUMANS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 27244453909     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088298     Document Type: Editorial

References (16)

1. Harley CB: Human ageing and telomeres. Ciba Found Symp 1997;211:129-139.
2. Greider CW: Telomerase activation. One step on the road to cancer? Trends Genet 1999;15:109-112.
3. Bryan TM, Englezou A, la-Pozza L, Dunham MA, Reddel RR: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997;3:1271-1274.
4. Blasco MA, Hahn WC: Evolving views of telomerase and cancer. Trends Cell Biol 2003;13:289-294.
5. Keith WN, Bilsland A, Evans TR, Glasspool RM: Telomerase-directed molecular therapeutics. Expert Rev Mol Med 2002;2002:1-25.
6. Nguyen B, Elmore LW, Holt SE: Telomerase as a target for cancer immunotherapy. Cancer Biol Ther 2003;2:131-136.
7. Hiyama E, Hiyama K: Clinical utility of telomerase in cancer. Oncogene 2002;21:643-649.
8. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW: Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249-255.
9. Poremba C, Scheel C, Hero B, Christiansen H, Schaefer KL, Nakayama J, Berthold F, Juergens H, Boecker W, Dockhorn-Dworniczak B: Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol 2000;18:2582-2592.
10. Krams M, Hero B, Berthold F, Parwaresch R, Harms D, Rudolph P: Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Am J Pathol 2003;162:1019-1026.
11. Sanz-Casla MT, Vidaurreta M, Maestro ML, Fernández C, Jiménez F Arroyo M, Cerdán FJ: Telomerase activity as a prognostic factor in colorectal cancer. Onkologie 2005;28:553-557.
12. Brummendorf TH, Lansdorp PM, Rufer N: Telomere length dynamics in normal and malignant hematopoiesis. J Anti-Aging Med 2000;3:395-407.
13. Brummendorf TH, Holyoake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ, Eaves AC, Lansdorp PM: Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000;95:1883-1890.
14. Boultwood J, Peniket A, Watkins F, Shepherd P, McGale P, Richards S, Fidler C, Littlewood TJ, Wainscoat JS: Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood 2000;96:358-361.
15. Drummond M, Lennard A, Brummendorf T, Holyoake T: Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. Leuk Lymphoma 2004;45:1775-1781.
16. Brummendorf TH, Ersoez I, Hartmann U, Bartolovic K, Balabanov S, Wahl A, Paschka P, Kreil S, Lahaye T, Berger U, Gschaidmeier H, Bokemeyer C, Hehlmann R, Dietz K, Lansdorp PM, Kanz L, Hochhaus A: Telomere length in peripheral blood cells reflects response to treatment with Imatinib in patients with chronic myeloid leukemia. Blood 2003;101:375-376.